UBS Group
TNGX icon

UBS Group’s Tango Therapeutics TNGX Stock Holding History

UBS Group’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.6M Sell
699,352
-291,106
-29% -$4.05M ﹤0.01% 2928
2025
Q4 		$8.78M Buy
990,458
+829,980
+517% +$7.15M ﹤0.01% 3428
2025
Q3 		$1.35M Sell
160,478
-116,624
-42% -$789K ﹤0.01% 5308
2025
Q2 		$1.42M Buy
277,102
+123,767
+81% +$306K ﹤0.01% 5138
2025
Q1 		$210K Sell
153,335
-261,138
-63% -$641K ﹤0.01% 6528
2024
Q4 		$1.28M Sell
414,473
-26,358
-6% -$122K ﹤0.01% 5121
2024
Q3 		$3.39M Buy
440,831
+289,516
+191% +$2.76M ﹤0.01% 3455
2024
Q2 		$1.3M Sell
151,315
-6,911
-4% -$53.4K ﹤0.01% 4178
2024
Q1 		$1.26M Buy
+158,226
New +$1.7M ﹤0.01% 4407
2023
Q4 		– Sell
-30,988
Closed -$349K – 9889
2023
Q3 		$349K Sell
30,988
-147
-0.5% -$896 ﹤0.01% 4933
2023
Q2 		$103K Buy
31,135
+10,643
+52% +$38.3K ﹤0.01% 5986
2023
Q1 		$80.9K Buy
20,492
+4,031
+24% +$23.4K ﹤0.01% 6096
2022
Q4 		$119K Buy
+16,461
New +$116K ﹤0.01% 5942
2022
Q3 		– Sell
-19,225
Closed -$87K – 10929
2022
Q2 		$87K Buy
19,225
+17,175
+838% +$104K ﹤0.01% 5533
2022
Q1 		$16K Sell
2,050
-534
-21% -$4.63K ﹤0.01% 7755
2021
Q4 		$28K Buy
+2,584
New +$31.1K ﹤0.01% 7462
2021
Q3 		– Sell
-3,259
Closed -$37K – 10089
2021
Q2 		$37K Buy
3,259
+460
+16% +$5.17K ﹤0.01% 6726
2021
Q1 		$31K Buy
2,799
+1,651
+144% +$19K ﹤0.01% 6992
2020
Q4 		$13K Sell
1,148
-150
-12% -$1.58K ﹤0.01% 7294
2020
Q3 		$13K Buy
+1,298
New +$13.3K ﹤0.01% 6649

Other funds holding TNGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

UBS Group's TNGX Position: Q1 2026 in Review

UBS Group reduced its Tango Therapeutics (TNGX) stake by 29% in Q1 2026, selling an estimated $4.05M and leaving 699,352 shares worth $14.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2928.

UBS Group first reported a position in TNGX in Q3 2020 and has held it in 20 quarters since. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • UBS Group held 699,352 shares of Tango Therapeutics worth $14.6M as of Q1 2026.
  • UBS Group sold 291,106 Tango Therapeutics shares in Q1 2026, an estimated $4.05M.
  • Tango Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2928 holding.
  • UBS Group first reported a position in Tango Therapeutics in Q3 2020 and has held it in 20 quarters since.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.